Patel @NaomiRheumMD et al. HbA1c in GiACTA. Tocilizumab assoc HbA1c reduction independent of steroids. Daily steroid dose assoc HbA1c @rheumnow #ACR22 Abstr#0461 https://t.co/9Nbewrpww8 https://t.co/NyeTyWICF6

• The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Tr…

Clinical pearl! Patient-reported treatment success in PsA assoc'd w/ control of arthritis, dactylitis, psoriasis, and health-related QoL. Top 3 pt-reported reasons for tx failure were pain, psoriasis and fatigue. Abs0393 #ACR22 @RheumNow https://t.co/F9RNI7EXcL https://t.co/7DcLaqUqnm

• Are We Meeting Patients' Treatment Goals with Guideline-Based Therapy for …

Smith et al. MMF equally good if not better for Black vs White patients with SSc-ILD. Suggests worse outcomes for Black patients relate to more severe disease at presentation rather than treatment failure @RheumNow #ACR22 Abstr#0521 https://t.co/xZtAt6Kw1f https://t.co/f0jG9jsgQ7

• Examination of Differential Response to Treatment with Mycophenolate Mofetil in…

Fukui et al. Retrospective study of alternate day steroids in IgG4-RD. No difference in flares. Significantly lower Glucocorticoid toxicity index -29.5 at 12 months -20 at 24 months. Not convinced until I see stronger data! @rheumnow #ACR22 Abstr#0128 https://t.co/20K4dKXE7R https://t.co/X4kJgCqhAE

• Advantages of Alternate-Day Glucocorticoid Treatment Strategy for IgG4-Related …

Maguire et al @Sineadm15 @bososhea Stronger relationship between disease activity and QoL in men than women with AxSpA. Our current tools may be inadequate to fully evaluate women with AxSpA @rheumnow #ACR22 Abstr#0406 https://t.co/duHqO0DXh3 https://t.co/yRcFiNpujT

• Are the BASDAI & BASFI Capturing the Full Impact of Disease Activity on Qua…

Woody Palmer fasciitis? Think cancer (esp ovarian CA in women) #acr22 @rheumnow https://t.co/c6nCATfGxt

Tofactinib efficacy for treatment of ankylosing spondylitis comparable across different BMI's. Regardless of BMI, tofacitinib better than placebo. BMI <25: more AE and SAE Abs#0405 @RheumNow #ACR22 https://t.co/qs3U4mjUXD

Rates of MACE and VTE with upadacitinib were infrequent and consistent with background rates in RA, PsA and AS patients. Factors associated with MACE/VTE: age>65, HTN, DM, smoking, history CV event/VTE Abs#0510 @RheumNow #ACR22 https://t.co/AjtJF0p3QK

Do you consider ttmt successful? Question Christeen et al. asked to 100+ PsA pts. 1/3 pts said no, they had > TJC, > SJC, > Pso & > dactylitis. Failure also w/: pain 24%, pso 15%, fatigue 12% and < ability to be active 9%. https://t.co/dQseCNSDBS Abstr #0393 #ACR22 @Rheumnow https://t.co/kGlmscsKL7

• Are We Meeting Patients&#039; Treatment Goals with Guideline-Based Therapy for …

MACE and VTE from 9 (6 RA, 2 PsA, 1 AS) RCTs w/ UPA. 6000+ pts received UPA 40-50% w/ > or = 2 BL CV risk factors. 41 MACE UPA 15mg RA-PsA group & 2 fatal VTE UPA 15mg RA group. Overlapping confidence intervals w/ADA & MTX. https://t.co/7xtZlDIkVu Abs#0510 #ACR22 @Rheumnow https://t.co/reywXk5Z0Z

• MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthriti…

RECITAL trial comparing ritux vs cyclo for CTD-ILD. This is a sub-group analysis of larger trial. 1/n @RheumNow #ACR22 #Plenary

GPA is a rare cause of both submandibular gland enlargement and dacryoadenitis. Can look like IgG4RD and Sjogrens. @RheumNow #ACR22 #Pearls https://t.co/Gw6OF4H2w2

Are my patients represented in PsA trials? @RheumNow #ACR22 Abstract #0090; Ignite Talk ☝️Of 25 RCT from 2002-2022, only 13 included patients of non-White race ☝️Hispanic/Latinx ethnicity was reported in 0 studies ☝️Black individuals represented < 1% patients included

Dr. John Stone pronounces GiACTA “GEE-ACTA”. I have been pronouncing it “GIA-ACTA” and will now correct myself #vasculitis #ACR22

#ACR22 Year in Review. Dr Langford summarised significant progress attained in 2022 in combating #COVID and protect our immunosuppressed patients @RheumNow https://t.co/lZSDRj3bkm